1.Advances in the Treatment of Glucocorticoid Resistance and Relapsed Immune Thrombocytopenia --Review.
Hui-Min PAN ; Rui-Ting WEN ; Zhi-Gang YANG
Journal of Experimental Hematology 2023;31(2):616-620
Immune thrombocytopenia (ITP) is an immune-mediated acquired hemorrhagic autoimmune disease. At present, the first-line therapeutic drugs for ITP include glucocorticoids and intravenous immunoglobulins. However, about 1/3 of the patients had no response to the first-line treatment, or relapsed after dose reduction or withdrawal of glucocorticoids. In recent years, with the gradual deepening of the understanding on the pathogenesis of ITP, the drugs targeting different pathogenesis continually emerge, including immunomodulators, demethylating agents, spleen tyrosine kinase (SYK) inhibitors and neonatal Fc receptor (FcRn) antagonist. However, most of these drugs are in clinical trials. This review summarized briefly the recent advances in the treatment of glucocorticoids resistance and relapsed ITP, so as to provide reference for the clinical treatments.
Infant, Newborn
;
Humans
;
Purpura, Thrombocytopenic, Idiopathic/drug therapy*
;
Glucocorticoids/therapeutic use*
;
Thrombocytopenia
;
Immunoglobulins, Intravenous/therapeutic use*
;
Immunologic Factors/therapeutic use*
2.The severe COVID-19: A sepsis induced by viral infection? And its immunomodulatory therapy.
Chinese Journal of Traumatology 2020;23(4):190-195
COVID-19 is known for its magical infectivity, fast transmission and high death toll based on the large number of infected people. From the perspective of the clinical manifestation, autopsy examination and pathophysiology, the essence of COVID-19 should be viewed as a sepsis induced by viral infection, and has the essential characteristics as sepsis induced by other pathogens. Therefore, in addition to etiological and supportive treatment, immunomodulatory therapy is also appropriate to severe COVID-19. Although there is still a lack of consensus on immunotherapy for sepsis so far, relatively rich experiences have been accumulated in the past decades, which will help us in the treatment of severe COVID-19. This article will elaborate immunotherapy of sepsis, though it may not be consistent.
Adrenal Cortex Hormones
;
therapeutic use
;
Betacoronavirus
;
Coronavirus Infections
;
complications
;
Glycoproteins
;
therapeutic use
;
Humans
;
Immunologic Factors
;
therapeutic use
;
Pandemics
;
Pneumonia, Viral
;
complications
;
Sepsis
;
drug therapy
;
etiology
;
Thymalfasin
;
therapeutic use
4.Discussion on the Focus of On-site Inspection of Clinical Trials of Lung Cancer Targeted Therapy and Immunotherapy Drugs.
Meng LI ; Lijing XU ; Xiuli LI ; Rong GAO
Chinese Journal of Lung Cancer 2022;25(7):506-510
As lung cancer targeted therapy and immunotherapy drugs are the current hot spot in the research and development area of new anti-tumor drugs, the amount of clinical trial in this area is increasing year by year. On the basis of combing the on-site inspections of drug registration clinical trials from 2019 to 2021, combined with the characteristics of lung cancer targeted therapy and immunotherapy drugs, this paper discusses the focus of on-site inspection of clinical trials of such drugs, and puts forward suggestions for the compliant implementation of lung cancer clinical trials.
.
Antineoplastic Agents/therapeutic use*
;
Humans
;
Immunologic Factors/therapeutic use*
;
Immunotherapy
;
Lung Neoplasms/drug therapy*
;
Molecular Targeted Therapy
5.Research Advances of Immunotherapy for Follicular Lymphoma --Review.
Li-Hua QIU ; Ya-Xin ZHENG ; Zhi-Rong ZHENG ; Chen TIAN
Journal of Experimental Hematology 2022;30(2):627-630
Follicular lymphoma is an indolent malignant tumor originating from lymph nodes and lymphoid tissues, which may affect the patients' quality of survival due to the recurrence and progression. In recent years, with the deepening understand of the molecular biology and signaling pathways, many new targeted drugs for follicular lymphoma have been discovered, such as monoclonal antibodies, checkpoint inhibitors, epigenetic regulation related targeted therapies and signaling pathway inhibitors. In this review, the new progress of immunotherapy for follicular lymphoma is summarized briefly.
Antineoplastic Agents/pharmacology*
;
Epigenesis, Genetic
;
Humans
;
Immunologic Factors/therapeutic use*
;
Immunotherapy
;
Lymphoma, Follicular/drug therapy*
6.Diagnosis and therapy of multiple myeloma.
Antonio PALUMBO ; Chiara CERRATO
The Korean Journal of Internal Medicine 2013;28(3):263-273
Many advances in the treatment of multiple myeloma have been made due to the use of transplantation and the introduction of novel agents including thalidomide, lenalidomide, and bortezomib. The first step is recognizing the symptoms and starting prompt treatment. Different strategies should be selected for young and elderly subjects. Young patients are commonly eligible for transplantation, which is now considered the standard approach for this setting, and various inductions therapies containing novel agents are available before transplantation. Elderly patients are usually not eligible for transplantation, and gentler approaches with new drugs combinations are used for their treatment.
Age Factors
;
Antineoplastic Agents/therapeutic use
;
Boronic Acids/therapeutic use
;
Humans
;
Immunologic Factors/therapeutic use
;
Multiple Myeloma/diagnosis/epidemiology/*therapy
;
Prognosis
;
Pyrazines/therapeutic use
;
Stem Cell Transplantation
;
Thalidomide/analogs & derivatives/therapeutic use
7.Molecular markers in prostate cancer. Part II: potential roles in management.
Sachin AGRAWAL ; Krishnaji P PATIL ; William D DUNSMUIR
Asian Journal of Andrology 2009;11(1):22-27
Predicting treatment responses in advanced prostate cancer (PCa) currently centres on prostate-specific antigen (PSA) kinetics and on being able to visualize measurable changes in imaging modalities. New molecular markers have emerged as potential diagnostic and prognostic indicators; these were summarized in Part I of this review in the Asian Journal of Andrology. A number of molecular markers are now being used to enhance PCa imaging and staging. However, management options for advanced and hormone-resistant PCa (HRPC) are limited and additional therapeutic options are needed. Molecular markers have been proposed as potential therapeutic targets using gene therapy and immunomodulation. Additionally, markers identified in early PCa and precursor lesions may offer novel targets for chemoprevention and vaccine development. This review summarizes the current advances regarding the roles of these markers in the management of PCa.
Antineoplastic Agents
;
therapeutic use
;
Biomarkers, Tumor
;
genetics
;
metabolism
;
Cancer Vaccines
;
therapeutic use
;
Genetic Therapy
;
Humans
;
Immunologic Factors
;
therapeutic use
;
Male
;
Prostate-Specific Antigen
;
blood
;
Prostatic Neoplasms
;
metabolism
;
therapy
8.Diagnosis and treatment of multiple myeloma in Hunan Province.
Feiyang LIU ; Qian CHENG ; Kui SONG ; Huan YU ; Junjun LI ; Hui ZHANG ; Guoyu HU ; Ming ZHOU ; Jun WANG ; Zhongqi DING ; Zimian LUO ; Ting PENG ; Liang DING ; Liang ZHAO ; Jing LIU ; Yanjuan HE ; Hongling PENG
Journal of Central South University(Medical Sciences) 2022;47(4):497-504
OBJECTIVES:
There is less clinical data on multiple myeloma (MM) in China, and the aim of this study was to collect and analyze the clinical data of newly diagnosed multiple myeloma (NDMM) patients in Hunan Province during 1 year, to understand the real clinical features and treatment outcome for Hunan Province patients with MM, and to strengthen the understanding of the standardized diagnosis process and treatment plan of MM.
METHODS:
The clinical data of 529 patients with NDMM in 12 large-scale general hospitals in Hunan Province from January 1 to December 31, 2019 were collected and analyzed, including baseline data, treatment regimens, duration of treatment, and adverse reactions. The clinical characteristics, treatment, and safety of patients were analyzed by SPSS 21.0.
RESULTS:
Among the 529 NDMM patients, the age was 33-90 (median 64) years and the male-female ratio was 1.38꞉1. The clinical features ranged from high to low were as follows: Bone pain (77.7%), anemia (66.8%), renal insufficiency (40.6%), hypercalcemia (15.1%). Typing: IgG 46.5%, IgA 24.6%, IgD 2.6%, IgM 0.8%, light chain 15.7%, double clone 3.0%, no secretion 0.6%, absence 6.2%. Staging: Durie-Salmon stage I, II, and III were 4.5%, 10.6%, 77.3%, respectively, and 40 cases (7.6%) missed this data. International Staging System (ISS) stage I, II, and III were 10.4%, 24.4%, and 47.6%, respectively, and 93 cases (17.6%) were missing. Revised International Staging System (R-ISS) stage I, II, and III were 5.5%, 27.0%, 23.1%, respectively, and 235 cases (44.4%) missed this data. Among the 98 NDMM patients in the Third Xiangya Hospital, Central South University, Durie-Salmon (DS) stage missing 2.0%, ISS stage missing 12.3%, and R-ISS stage missing 12.3%.Treatment: Among the 529 patients,475 received treatment, the rate of treatment was 89.8%; 67.4% of the patients were able to complete four courses of chemotherapy at induction phase, 90.3% of the patients received proteasome inhibitor based combination chemotherapy regimen more than once, 67.2% received immunomodulator based regimen more than once, and 59.8% of the patients received proteasome inhibitor and immunomodulator based combination chemotherapy regimen more than once. Curative: Overall response rate (ORR) and high quality response rate (HQR) of the 4-course group were better than those of the 2-course group (ORR: 85% vs 65%, P=0.006; HQR: 68.3% vs 24.0%, P<0.001). The HQR of the standard chemotherapy group was better than that of the non-standard chemotherapy group (65.1% vs 48.2%, P=0.035). Adverse reactions during treatment included hematologic toxicity (17.5%), peripheral neuropathy (24.8%), gastrointestinal adverse events (23.8%), pulmonary infection (25.9%), herpes zoster (4.6%), and venous thrombotic events (1.7%).
CONCLUSIONS
In 2019, the missed diagnosis rate of MM patients was high, the medium age of diagnosis was older, and the accuracy of patient diagnosis was not high. There is a great difference among medical centers, especially in the stage and risk stratified, nearly half of NDMM patients are not diagnosed with R-ISS stage; the lack of cytogenetic data needs to be supplemented by follow-up studies. A high proportion of patients with NDMM present with bone pain and anemia.Patients received treatment have higher use of chemotherapy regimens containing proteasome inhibitors and/or immunomodulators, but there is a significant gap among different medical centers, and standardized treatment needs to be strengthened. The safety during chemotherapy is controllable.
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
;
Female
;
Humans
;
Immunologic Factors/therapeutic use*
;
Male
;
Middle Aged
;
Multiple Myeloma/therapy*
;
Neoplasm Staging
;
Pain
;
Prognosis
;
Proteasome Inhibitors/therapeutic use*
9.Advances in understanding of idiopathic pulmonary fibrosis.
Chinese Medical Journal 2009;122(7):844-857
Adrenal Cortex Hormones
;
therapeutic use
;
Animals
;
Anticoagulants
;
therapeutic use
;
Antioxidants
;
therapeutic use
;
Humans
;
Idiopathic Pulmonary Fibrosis
;
diagnosis
;
drug therapy
;
pathology
;
therapy
;
Immunologic Factors
;
therapeutic use
;
Lung Transplantation
;
Pyridones
;
therapeutic use
10.POEMS syndrome--a case for more aggressive treatment.
Rahul RATHAKRISHNAN ; Te-Chih LIU ; Yee-Cheun CHAN ; Benjamin K C ONG
Annals of the Academy of Medicine, Singapore 2007;36(6):435-437
INTRODUCTIONPatients with POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal or M-protein and skin changes) syndrome exhibit a wide range of clinical manifestations and are often seen by a variety of specialists prior to diagnosis.
CLINICAL PICTUREWe describe a case of POEMS syndrome that first presented with significant neuropathy but progressed to develop further manifestations of the condition, including marked gastrointestinal symptoms.
TREATMENTThe patient was commenced on localised radiotherapy and chemotherapy in addition to immunomodulatory therapy for the neuropathy.
CONCLUSIONWe highlight several learning points that may benefit physicians from varied specialties. This case is also unique for its marked gastrointestinal manifestation. To our knowledge, this is the second reported case in the literature with this feature.
Gastrointestinal Diseases ; etiology ; physiopathology ; Humans ; Immunologic Factors ; therapeutic use ; Male ; Middle Aged ; POEMS Syndrome ; complications ; drug therapy ; radiotherapy ; Treatment Outcome